E3024 is a novel, selective and competitive dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes

被引：0
|
作者：
Yasuda, Nobuyuki
Nagakura, Tadashi
Inoue, Takashi
Yamazaki, Kazuto
Katsutani, Naruo
Takenaka, Osamu
Clark, Richard
Matsuura, Fumiyoshi
Emori, Eita
Yoshikawa, Seiji
Kira, Kazunobu
Okada, Toshimi
Ikuta, Hironori
Saeki, Takao
Asano, Osamu
Tanaka, Isao
机构：
来源：
DIABETES | 2006年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A349 / A349
页数：1
相关论文
共 50 条
  • [21] Evaluation of Dipeptidyl Peptidase-IV Inhibitor Use in Hospitalized Patients With Diabetes
    Petite, Sarah E.
    Hill, Maja C.
    ANNALS OF PHARMACOTHERAPY, 2021, 55 (11) : 1326 - 1332
  • [22] JANUVIA® and beyond: Selective dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes
    Weber, Ann E.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [23] The effect of dipeptidyl peptidase-IV inhibition on the immune functions in patients with type 2 diabetes
    Sromova, L.
    Busek, P.
    Mareckova, H.
    Potockova, J.
    Andel, M.
    Sedo, A.
    FEBS JOURNAL, 2014, 281 : 173 - 173
  • [24] The effect of dipeptidyl peptidase-IV inhibition on bone in a mouse model of type 2 diabetes
    Gallagher, Emily Jane
    Sun, Hui
    Kornhauser, Caroline
    Tobin-Hess, Aviva
    Epstein, Sol
    Yakar, Shoshana
    LeRoith, Derek
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2014, 30 (03) : 191 - 200
  • [25] Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes
    Mari, A
    Sallas, WM
    He, YL
    Watson, C
    Ligueros-Saylan, M
    Dunning, BE
    Deacon, CF
    Holst, JJ
    Foley, JE
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (08): : 4888 - 4894
  • [26] Inhibitors of dipeptidyl peptidase IV:: a novel approach for the prevention and treatment of Type 2 diabetes?
    Deacon, CF
    Ahrén, B
    Holst, JJ
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (09) : 1091 - 1102
  • [27] To investigate the efficacy of dipeptidyl peptidase-IV (DPP-IV) inhibitor therapy in multiethnic Asian patients with type 2 diabetes mellitus
    Andres, Julia
    Yeo, Jia Xuan
    Khoo, Chin Meng
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S123 - S124
  • [28] A manganese-salen complex as dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
    Zhu, Ming-rong
    Zhou, Jie
    Jin, Yi
    Gao, Li-Hui
    Li, Ling
    Yang, Jun-Ru
    Lu, Chun-Mei
    Zhao, Qi Hua
    Xie, Ming-jin
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2018, 120 : 1232 - 1239
  • [29] RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes (vol 652, pg 157, 2011)
    Singh, Shuchita
    Roy, Subhasis
    Sethi, Sachin
    Benjamin, Biju
    Sundaram, Sindhuja
    Khanna, Vivek
    Kandalkar, Sachin R.
    Pal, Chanchal
    Kant, Rajiv
    Patra, Ashok Kumar
    Rayasam, Geetavani
    Mittra, Shivani
    Saini, Kulvinder Singh
    Paliwal, Jyoti
    Chugh, Anita
    Ahmed, Shahadat
    Sattigeri, Jitendra
    Cliff, Ian
    Ray, Abhijit
    Bansal, Vinay S.
    Bhatnagar, Pradip Kumar
    Davis, Joseph Alex
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2011, 655 (1-3) : 121 - 121
  • [30] Pharmacological profile of GRC 8011, a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor
    Anupindi, R.
    Gharat, L.
    Shah, D. M.
    Varanasi, K.
    Vakkalanka, S. V. S.
    Majumdar, U. K.
    Gupta, M.
    Narayanan, S.
    DIABETOLOGIA, 2006, 49 : 402 - 403
12345